title: In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.
abstract: Over the years, a large number of drugs have been used in isolated perfusion of extremities or organs. To interpret the pharmacokinetics of these drugs correctly, the contributions of tissue or organ clearance and chemical degradation, respectively, to overall drug elimination from the circuit need to be identified. In support of a phase I clinical trial of isolated hepatic perfusion (IHP), delivering 5-fluorouracil (5-FU) and oxaliplatin to patients with colorectal cancer hepatic metastases, we aimed to characterize the stability of 5-FU and oxaliplatin in the IHP circuit. Stability of 5-FU and oxaliplatin was assessed in human blood, lactated Ringer infusion (LRI), and in an in vitro IHP circuit consisting of both blood and LRI. Samples were analyzed with liquid chromatography tandem mass spectrometry (5-FU) and atomic absorption spectrophotometry (oxaliplatin). 5-FU was stable under all tested in vitro conditions, but ultrafilterable platinum concentrations decreased slowly with a half-life of 85 minutes in both IHP perfusate and whole blood. The stability of 5-FU in the media containing blood is likely attributable to saturation of dihydropyrimidine dehydrogenase. The decrease of ultrafilterable platinum in blood-containing media with an 85 minutes half-life is in agreement with previous reports on oxaliplatin biotransformation. Oxaliplatin and 5-FU are sufficiently stable in the circuit for the 1-hour perfusion in ongoing and planned clinical trials.
authors.affiliation: Shadyside Hospital Perfusion Services, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
authors.forename: Heidi
authors.initials: H
authors.lastname: Colville
authors.forename: Ryan
authors.initials: R
authors.lastname: Dzadony
authors.forename: Rebecca
authors.initials: R
authors.lastname: Kemp
authors.forename: Stephen
authors.initials: S
authors.lastname: Stewart
authors.forename: Herbert J
authors.initials: HJ
authors.lastname: Zeh
authors.forename: David L
authors.initials: DL
authors.lastname: Bartlett
authors.forename: Julianne
authors.initials: J
authors.lastname: Holleran
authors.forename: Kevin
authors.initials: K
authors.lastname: Schombert
authors.forename: Juliann E
authors.initials: JE
authors.lastname: Kosovec
authors.forename: Merrill J
authors.initials: MJ
authors.lastname: Egorin
authors.forename: Jan H
authors.initials: JH
authors.lastname: Beumer
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000737:chemistry*; D001774:Blood Chemical Analysis; D004355:Drug Stability; D005472:Fluorouracil / Q000737:chemistry*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D008099:Liver; D009944:Organoplatinum Compounds / Q000737:chemistry*; D000077150:Oxaliplatin; D010477:Perfusion / Q000379:methods
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil